Product Pathways - Metabolism
SignalSilence® MTAP siRNA II #6285
|6285S||300 µl (3 nmol)||---||In Stock||---|
|6285||carrier free and custom formulation / quantity||email request|
Product is assembled upon order. Please allow up to three business days for your product to be processed.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® MTAP siRNA I #6284 (+) or SignalSilence® MTAP II (+), using MTAP Antibody #4158 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The MTAP Antibody confirms silencing of MTAP expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
SignalSilence® MTAP siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit MTAP expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM MTAP siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
MTAP is an enzyme that is essential for the salvage pathway for both adenine and methionine synthesis. MTAP catalyzes the cleavage of 5’-methylthioadenosine into adenine and 5-methylthio-D-ribose-1-phosphate. Adenine is then used to generate AMP whereas 5-methylthio-D-ribose-1-phosphate is converted into methionine (1,2). MTAP is expressed in all normal cells and tissues, although frequently lost in different human tumors including pancreatic adenocarcinoma, neuroendocrine tumors, non-small cell lung carcinoma and breast carcinoma. MTAP is usually codeleted with p16 (cdkN2a/ARF) (3-5). MTAP overexpression in breast cancer cells inhibits their ability to form colonies in soft agar, thereby implicating its function as a tumor suppressor (6).
- Backlund, P.S. and Smith, R.A. (1981) J Biol Chem 256, 1533-5.
- Backlund, P.S. et al. (1982) J Biol Chem 257, 4196-202.
- Dreyling, M.H. et al. (1998) Genes Chromosomes Cancer 22, 72-8.
- Zhang, H. et al. (1996) Cancer Genet Cytogenet 86, 22-8.
- Illei, P.B. et al. (2003) Clin Cancer Res 9, 2108-13.
- Christopher, S.A. et al. (2002) Cancer Res 62, 6639-44.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.